Original articles – Obstetrics

Retinol binding protein 4 – a novel association with early-onset preeclampsia

Edi Vaisbuch[1,2], Roberto Romero[1,2,3,*], Shali Mazaki-Tovi[1,2], Offer Erez[1,2], Sun Kwon Kim[1], Tinnakorn Chaiworapongsa[1,2], Francesca Gotsch[1], Nandor Gabor Than[1], Zhong Dong[1], Percy Pacora[1], Ronald Lamont[1,2], Lami Yeo[1,2], Sonia S. Hassan[1,2] and Juan Pedro Kusanovic[1,2]

[1] Intramural Division, Perinatology Research Branch, NICHD/NIH/DHHS, Hutzel Women's Hospital, Bethesda, MD, and Detroit, MI, USA

[2] Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, Detroit, MI, USA

[3] Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA

Abstract

Objective: Dysregulation of maternal circulating adipokines has been implicated in several ''great obstetrical syndromes'' including preeclampsia (PE), small-for-gestational age (SGA) neonate and fetal death (FD). It has been suggested that adipokines provide a molecular link between metabolic derangements and inflammatory response in complicated pregnancies. Retinol binding protein 4 (RBP4), a novel adipokine, plays a role in obesity-related disorders, as well as in the regulation of the immune response. The aim of this study was to determine whether there are changes in maternal plasma concentrations of RBP4 in patients with PE and in those with an SGA neonate or FD.

Study design: This cross-sectional study included patients in the following groups: 1) normal pregnancy (n=134); 2) PE (n=104); 3) SGA neonate (n=28); and 4) FD (n=37). Maternal plasma RBP4 concentrations were determined by ELISA. Non-parametric statistics were used for analysis.

Results: 1) The median maternal plasma RBP4 concentration was higher among patients with PE than in those with a normal pregnancy (P=0.03); 2) The median maternal plasma RBP4 concentrations of patients with preterm PE (<37 weeks) was higher than that of those with term PE (P=0.017) and than that of those with a normal pregnancy (P=0.002); 3) The median maternal plasma RBP4 concentration did not differ significantly between patients with a normal pregnancy and those with an SGA neonate or with an FD; 4) Among normal pregnant women, the maternal plasma RBP4 concentrations did not correlate with pre-pregnancy body mass index, gestational age at blood sampling and neonatal birthweight.

Conclusions: 1) Preeclampsia, but not pregnancy with an SGA neonate or an FD, is associated with a higher median maternal plasma concentration of RBP4 than normal pregnancy; 2) Preterm PE, and specifically early-onset PE, is associated with higher median RBP4 concentrations in maternal plasma compared to term PE. These findings suggest a role for RBP4 in the pathogenesis of preterm PE, but not in SGA and FD.

Keywords: Adipokines; fetal death (FD); fetal demise; intrauterine fetal death (IUFD); pregnancy; RBP4; small-for-gestational age (SGA) neonate.

*Corresponding author:
Roberto Romero, MD
Intramural Division, Perinatology Research Branch
NICHD/NIH/DHHS, Hutzel Women's Hospital-Box No. 4
3990 John R
Detroit
MI 48201
USA
Tel.: +1 (313) 993-2700
Fax: +1 (313) 993-2694
E-mail: prbchiefstaff@med.wayne.edu

Introduction

Preeclampsia is a leading cause of maternal and perinatal mortality and morbidity [27, 61, 106, 110], and together with small-for-gestational age (SGA) neonate and fetal death (FD) are part of the ''great obstetrical syndromes'' [102]. Consistent with the syndromic nature of these conditions, several mechanism of disease have been associated with their clinical manifestations, such as an anti-angiogenic state [17, 18, 30, 31, 38, 57, 59, 60, 65, 103, 122, 126], abnormal physiologic transformation of the spiral arteries [14, 15, 26, 83, 91], chronic uteroplacental ischemia [12, 41, 85, 100, 108], increased trophoblast apoptosis/necrosis [51] and endothelial cell dysfunction [22, 36, 92, 97, 99, 119]. Notably, preeclampsia, SGA and FD have all been associated with maternal metabolic complications such as obesity [23, 29, 110, 111, 129], insulin resistance [34, 52, 115, 131] and dyslipidemia [42, 128]. In addition, these women have an increased risk of metabolic syndrome-related morbidity [20, 39, 44, 109] and mortality [49, 53, 113] later in life.

Adipokines are a family of biologically active adipocyte-derived cytokines/hormones, such as leptin, adiponectin, visfatin and resistin, as well as tumor necrosis factor (TNF), interleukin (IL)-6, IL-1 and monocyte chemotactic protein-1 (MCP-1) [120]. Adipokines have been implicated in the physiology and pathophysiology of glucose homeostasis, providing a link between obesity, insulin resistance and type 2 diabetes mellitus (DM) [120]. In addition, adipocytokines play a role in the pathophysiology of inflammatory disorders

such as asthma [43], inflammatory bowel disease [6, 123], rheumatoid arthritis [10, 105] and obesity [32, 121, 132, 133]. Alterations in circulating concentrations of adipokines such as leptin, adiponectin, visfatin and TNF-α have been associated with the pathogenesis of preeclampsia [24, 25, 45, 64, 79, 86, 95], SGA [72, 81] and FD [89], as well as other complications of pregnancy [58, 68–71, 73–78, 80, 82, 87, 88, 125].

Retinol binding protein 4 (RBP4), previously thought to be only a specific carrier for retinol and be produced mainly by the liver, has recently [132] been added to the rapidly expanding family of adipokines. RBP4 is suggested to have a role in obesity-induced insulin resistance and, like other adipokines, increased circulating RBP4 concentrations have been reported in patients with diabetes [132] as well as in those destined to develop overt diabetes [21, 40]. Thus, lowering RBP4 concentrations has been suggested as a potential therapeutic target in type 2 DM [40, 118, 132]. Furthermore, RBP4 may play a role in inflammation [5, 134]. Indeed, in non-diabetic human subjects, RBP4 gene expression was found to be strongly associated with inflammatory markers of adipose tissue such as CD68 and MCP-1 [134].

Currently, there is only one report [117] of RBP4 concentrations in patients with preeclampsia which found no association between maternal circulating concentrations of RBP4 and preeclampsia. Moreover, there are no data regarding changes in circulating RBP4 in patients with SGA or FD. The aim of this study was to determine whether maternal plasma concentration of RBP4 is associated with preeclampsia, delivery of an SGA neonate or an FD.

Materials and methods

Study groups and inclusion criteria

A retrospective cross-sectional study was conducted comprising women in the following groups: 1) normal pregnant women (n=134); 2) patients with preeclampsia (n=104); 3) pregnant women without preeclampsia or hypertension who delivered an SGA neonate (n=28); and 4) patients without preeclampsia or hypertension who had an FD (n=37). Women with multiple pregnancies or fetuses with congenital and/or chromosamal anomalies were excluded.

Samples and data were retrieved from our bank of biological samples and clinical databases. Many of these samples have previously been used to study the biology of inflammation, hemostasis, and angiogenesis regulation in normal pregnant women and those with pregnancy complications.

All participants provided written informed consent prior to the collection of maternal blood. The collection of maternal blood and its use for research purposes was approved by the Institutional Review Boards of the Sotero del Rio Hospital (Chile), Wayne State University (Detroit, Michigan, USA) and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD/NIH/DHHS).

Clinical definitions

Women with a normal pregnancy were defined as those without medical, obstetrical, or surgical complications at the time of the study and who subsequently delivered at term (>37 weeks of gestation) an appropriate-for-gestational age infant [3], without neonatal complications. Preeclampsia was defined as the onset of hypertension (systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg on at least two occasions, 4 h to 1 week apart) after 20 weeks of gestation with proteinuria (≥ 300 mg in a 24 h urine collection or at least one dipstick measurement $\geq 2+$) [1]. Severe preeclampsia was diagnosed according to the criteria proposed by the American College of Obstetricians and Gynecologists (ACOG) committee [1]. Preterm preeclampsia was defined as the development of preeclampsia before 37 completed weeks of gestation. Patients with preeclampsia were further classified as either having early-onset (<32 weeks), or late-onset (≥ 32 weeks) disease according to the gestational age at which preeclampsia was diagnosed. SGA was defined as birthweight below the 10th percentile [3]. Women with an FD included those with a singleton pregnancy and FD diagnosed after 20 weeks of gestation. FD was determined by absence of heart motion on ultrasound examination. The body mass index (BMI) was calculated using the formula: weight (kg)/height (m^2). The study population was classified according to the pre-pregnancy BMI into two groups: normal weight (BMI <25 kg/m^2) and overweight/obese (BMI ≥ 25 kg/m^2) women [2].

Sample collection and determination of RBP4 in maternal plasma

Maternal blood samples were obtained once from each woman at the time of diagnosis and collected in vials containing ethylenediaminetetraacetic acid. The samples were then centrifuged at $1300 \times g$ for 10 min at 4°C and the obtained plasma was stored at −80°C until assayed. Maternal plasma concentration of RBP4 was determined by sensitive enzyme-linked immunoassays (Millipore Corporation, St. Charles, MO, USA). The RBP4 immunoassay was validated for human plasma in our laboratory, prior to the conduction of this study. Immunoassays were carried out according to the manufacturer's recommendations. The calculated inter- and intra-assay coefficients of variation for RBP4 immunoassays in our laboratory were 5% and 5.1%, respectively. The sensitivity was calculated to be 0.10 ng/mL.

Statistical analysis

Normality of the data was tested using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Since maternal plasma RBP4 concentrations were not normally distributed, Kruskal-Wallis test with post-hoc analysis by Mann-Whitney *U*-test were used for comparisons of continuous variables. Comparison of proportions was performed using χ^2 or Fisher's exact tests. Correlations between RBP4 concentrations and pre-pregnancy BMI and gestational age at blood sampling were examined using Spearman's rank correlation test. A $P<0.05$ was considered statistically significant. Analysis was performed with SPSS, version 14 (SPSS Inc., Chicago, IL, USA).

Results

Demographic and clinical characteristics of women with a normal pregnancy, preeclampsia, an SGA neonate and an FD are listed in Table 1. Compared to women with a normal pregnancy, patients with pre-eclampsia had a higher rate of nulliparity, women with an SGA neonate were more likely to smoke and to have a lower pre-pregnancy BMI, and those

with an FD had a lower median gestational age at blood sampling. All three groups had a lower median gestational age at delivery and a lower median neonatal birthweight than women with a normal pregnancy.

Maternal plasma RBP4 concentration in normal pregnancy

RBP4 was detected in the maternal plasma of all subjects included in this study. Among women with a normal pregnancy, maternal plasma RBP4 concentration did not correlated with pre-pregnancy BMI (Spearman's ρ –0.64, P=0.6), gestational age at blood sampling (Spearman's ρ –0.038, P=0.7) or neonatal birthweight (Spearman's ρ –0.032, P=0.8). In addition, the median maternal plasma RBP4 concentration did not differ significantly between women with a normal BMI and overweigh/obese women (median 9025.5 ng/mL, IQR 7681.9–10811 vs. 9023.4 ng/mL, IQR 7272.0–10506.7, respectively; P=0.8). Similarly, there was no significant difference between women who smoked and those who did not (median 8102.5 ng/mL, IQR 7090.3–10332.8 vs. 9168.8 ng/mL, IQR 7602.9–10245.9, respectively; P=0.3).

Maternal plasma RBP4 concentration in patients with preeclampsia

The median maternal plasma RBP4 concentration was higher in women with preeclampsia than in those with a normal pregnancy (9769.3 ng/mL vs. 9080.9 ng/mL, P=0.03; Figure 1). In patients with pre-eclampsia, the maternal plasma RBP4 concentrations correlated with gestational age at blood sampling (Spearman's ρ –0.34, P<0.001) and neonatal birth-

weight (Spearman's ρ –0.31, P=0.01, but not with pre-pregnancy BMI (Spearman's ρ –0.03, P=0.77). The median maternal plasma RBP4 concentration did not differ significantly between women with a normal BMI and overweight/obese women with preeclampsia (9888.4 ng/mL vs. 9932.2 ng/mL, respectively; P=0.9).

RBP4 in preterm preeclampsia (<37 weeks' gestation)

Among patients with preeclampsia, 37% (39/104) had preterm preeclampsia. The median maternal plasma RBP4 concentration of these women was higher than that in those with preeclampsia at term (10257.6 ng/mL vs. 9018.3 ng/mL, P=0.017; Figure 2). Similarly, patients with preterm preeclampsia had a higher median RBP4 concentration than women with a normal pregnancy (10257.6 ng/mL vs. 9080.9 ng/mL, P=0.002; Figure 2). There was no significant difference in the median maternal plasma RBP4 concentration between women with term preeclampsia and those with a normal pregnancy (P=0.8, Figure 2).

RBP4 in early-onset preeclampsia (<32 weeks' gestation)

Early-onset preeclampsia (<32 weeks' gestation) was diagnosed in 27% (28/104) of patients with preeclampsia. The demographic and clinical characteristics of women with early and late-onset preeclampsia (≥32 weeks' gestation) are displayed in Table 2. The median maternal plasma RBP4 concentration of women with early-onset preeclampsia was higher than in those diagnosed with preeclampsia at

Table 1 Demographic and clinical characteristics of the study population.

	Normal pregnancy (n=134)	PE (n=104)	P[1]	SGA (n=28)	P[2]	FD (n=37)	P[3]
Maternal age (years)	25 (21–29)	23.5 (20–29)	NS	23 (20–28.5)	NS	27 (25–29.5)	NS
Ethnicity, African American	79.5 (105/132)	81.7 (85)	NS	89.3 (25)	NS	88.9 (32/36)	NS
Smoking	17.4 (23/132)	13.5 (14)	NS	42.9 (12)	0.005	32.4 (12)	NS
Nulliparity	27.6 (37)	62.5 (65)	<0.001	46.4 (13)	NS	29.7 (11)	NS
Pre-pregnancy BMI (kg/m^2)	26.4 (22.6–33.1)	26.6 (23.5–30.0)	NS	23.1 (18.5–28.8)	0.027	27.9 (24.9–32.9)	NS
Gestational age at blood sampling (weeks)	37.6 (31.1–39.1)	36.0 (31.6–38.5)	NS	37.4 (34.7–38.4)	NS	31 (26.9–36.6)	0.002
Gestational age at delivery (weeks)	39.3 (38.7–40.2)	36 (32.3–38.6)	<0.001	37.6 (36.3–38.4)	<0.001	31 (27.4–36.7)	<0.001
Sample storage time (years)	7.7 (6.8–8.1)	7.5 (6.8–8.0)	NS	7.3 (6.6–7.6)	NS	7.5 (6.8–7.9)	NS
Birth weight (g)	3342 (3100–3629)	2195 (1480–2815)	<0.001	2240 (1897–2470)	<0.001	1417 (779–2263)	<0.001

Values are expressed as median (interquartile range) or % (number). P[1]=between preeclampsia and normal pregnancy, P[2]=between SGA and normal pregnancy, P[3]=between FD and normal pregnancy.
PE=preeclampsia, SGA=small-for gestational age, FD=fetal death, BMI=body mass index, NS=not significant.

Figure 1 Box and whisker plot of the comparison of the median plasma RBP4 concentrations of women with a normal pregnancy and those with preeclampsia, SGA or FD. The median maternal plasma concentration of RBP4 was higher in patients with pre-eclampsia than in those with a normal pregnancy (9769.3 ng/mL, interquartile range (IQR) 7780.2–11732.8 vs. 9080.9 ng/mL, IQR 7284.4–10741.3, P = 0.03). The median maternal plasma concentration of RBP4 was not significantly different between patients with a normal pregnancy (9080.9 ng/mL, IQR 7284.4–10741.3), those with an SGA neonate (8831.3 ng/mL, IQR 7223.9–10056.1, P = 0.6) and pregnant women with an FD (8877.3 ng/mL, IQR 7730.4–10878.9, P = 0.7).

≥32 weeks of gestation (11427 ng/mL vs. 9260.0 ng/mL, P < 0.001; Figure 3), as well as than in women with a normal pregnancy (11427 ng/mL, vs. 9080.9 ng/mL, P < 0.001; Figure 3). In contrast, the median maternal plasma RBP4 concentration did not differ significantly between patients with preeclampsia diagnosed ≥32 weeks of gestation and normal pregnant women (P = 0.8).

RBP4 in severe preeclampsia and preeclampsia with an SGA neonate

Among patients with preeclampsia, 80% (83/104) had severe preeclampsia, and 49% (51/104) delivered an SGA neonate. There was no significant difference in the median maternal plasma concentration of RBP4 between patients with severe preeclampsia and those with mild preeclampsia (9810.9 ng/mL, IQR 7816.1–11715.7 vs. 9724.7 ng/mL, IQR 7699.4–11754.2, respectively; P = 0.7). Similarly, the median maternal plasma RBP4 concentration did not differ significantly between patients with preeclampsia with or without an SGA neonate (9721.6 ng/mL, IQR 8249.3–12393.2 vs. 9837.5 ng/mL, IQR 7603.4–11698.4, respectively; P = 0.6).

Figure 2 Box and whisker plot of the comparison of the median maternal plasma RBP4 concentration of patients with preterm (< 37 weeks gestation) and term preeclampsia. The median maternal plasma RBP4 concentration among women with preterm preeclampsia was higher than in patients with a normal pregnancy (10257.6 ng/mL, IQR 8690.4–12500.4 vs. 9080.9 ng/mL, IQR 7284.4–10741.3, P = 0.002), as well as those with term pre-eclampsia (9018.3 ng/mL, IQR 7451.4–10768.7, P = 0.017). The median RBP4 concentration in maternal plasma did not differ significantly between normal pregnant women and those with term preeclampsia (P = 0.8).

Maternal plasma RBP4 in patients with an SGA neonate or an FD

Among normotensive women with an SGA neonate, 82% (23/28) had a neonate with a birthweight < 5th centile for gestational age. The median maternal plasma concentration of RBP4 was not significantly different between women with an SGA neonate and those with a normal pregnancy (8831.3 ng/mL vs. 9080.9 ng/mL, respectively; P = 0.6; Figure 1). There was no significant difference in the median maternal plasma RBP4 concentration of women with severe SGA (< 5th centile for gestational age) and those whose neonates weighed between the 5th and < 10th centiles for gestational age (8938.3 ng/mL, IQR 7112.6–10328.8 vs. 7818.0 ng/mL, IQR 7079.7–9833.9, respectively; P = 0.5).

Similarly, the median maternal plasma RBP4 concentrations did not differ significantly between women with an FD and those with a normal pregnancy (8877.3 ng/mL vs. 9080.9 ng/mL, respectively; P = 0.7; Figure 1).

Discussion

Principal findings of the study

1) Patients with preeclampsia had a higher median maternal plasma concentration of RBP4 than women with a normal

Table 2 Demographic and clinical characteristics of patients with early-onset preeclampsia and those with preeclampsia diagnosed ≥32 weeks of gestation.

	Gestational age at diagnosis of preeclampsia		P
	<32 weeks (n=28)	≥32 weeks (n=76)	
Maternal age (years)	24.5 (20–31.7)	23.5 (19–27.7)	NS
Ethnicity, African American	67.9 (19)	86.8 (66)	NS
Smoking	10.7 (3)	16.9 (11)	NS
Nulliparity	67.9 (19)	60.5 (46)	NS
Pre-pregnancy BMI (kg/m^2)	26.8 (23.5–29.7)	26.6 (23.1–30.1)	NS
Gestational age at blood sampling (weeks)	29.5 (27.5–30.5)	37.2 (34.6–39)	<0.001
Gestational age at delivery (weeks)	30.1 (27.7–31.7)	37.3 (35.1–39)	<0.001
Sample storage time (years)	7.4 (7.1–7.9)	7.5 (6.7–8.1)	NS
Birth weight (g)	1150 (775–1370)	2590 (2025–2995)	<0.001

Values are expressed as median (interquartile range) or % (number).
BMI=body mass index, NS=not significant.

pregnancy; 2) Early-onset preeclampsia (<32 weeks) is associated with a higher median maternal plasma RBP4 concentration than late-onset preeclampsia; 3) The median maternal plasma RBP4 concentrations of women with an

Figure 3 Box and whisker plot of the comparison of the median maternal plasma RBP4 concentration of patients with early-onset preeclampsia (<32 weeks' gestation) and those with preeclampsia diagnosed ≥32 weeks' gestation. The median maternal plasma RBP4 concentration of patients with early-onset preeclampsia was higher than in women with a normal pregnancy (11427 ng/mL, IQR 9852.9–13560.0 vs. 9080.9 ng/mL, IQR 7284.4–10741.3, P<0.001) and than those with preeclampsia diagnosed ≥32 weeks' gestation (9260.0 ng/mL, IQR 7456.0–10880.9, P<0.001). The median RBP4 concentration in maternal plasma did not differ significantly between normal pregnant women and those with preeclampsia diagnosed ≥32 weeks' gestation (P=0.8).

SGA neonate or FD did not differ significantly from normal pregnant women.

RBP4 – a novel adipokine

Retinol binding protein [55] belongs to the lipocalin family and is a specific carrier of retinol from the liver to peripheral tissues. RBP4 is a plasma protein [101], while RBP1, RBP2 [28], RBP5 and RBP7 are cellular proteins, and RBP3 is the interstitial form [62].

Although RBP is mainly synthesized by the liver [93], subsequent studies demonstrated that it is also produced by adipocytes [66, 84]. Only recently, RBP4 has been characterized as a novel adipokine when its role in the pathogenesis of insulin resistance has been proposed [132]. RBP4, similar to other adipokines [11, 58, 63, 73–75, 86–88, 112, 120, 121, 132, 133], has also been linked to inflammation [5, 134]. Gene expression of RBP4 was found to be strongly associated with inflammatory markers (i.e., CD68 and MCP-1) of adipose tissue in non-diabetic human subjects [134]. In children, RBP4 concentrations correlated not only with indices of obesity and insulin resistance but also with inflammatory factors such as C-reactive protein and IL-6 [5].

RBP4 concentration during normal gestation

Among women with a normal pregnancy, there was no correlation between RBP4 concentrations and maternal age, gestational age at blood sampling, pre-pregnancy BMI and neonatal birthweight. In addition, there was no difference in the median RBP4 concentrations between normal weight and overweight/obese patients, as well as between healthy pregnant women who smoked and those who did not.

Our findings are in agreement with a recent report by Stepan et al. [117] in which RBP4 was not associated with gestational age at blood sampling, gestational age at delivery and neonatal birthweight. The authors also reported a lack of correlation between RBP4 and markers of adiposity (BMI, leptin), insulin resistance (fasting glucose, fasting insulin, HOMA-IR and adiponectin) and lipid metabolism (cholesterol, triglycerides) [117]. Similarly, no change in circulating

RBP with increasing gestational age was reported [7, 19, 35, 37]. The results of our study demonstrate lack of correlation over a wide range of gestational age (20–42 weeks' gestation) and that there is no difference in RBP4 concentrations between normal weight and overweight/obese pregnant women.

RBP4 concentration is elevated in preterm preeclampsia but not in term preeclampsia

The finding that the median maternal plasma concentration of RBP4 is higher in patients with preeclampsia than in women with a normal pregnancy is novel. Moreover, among patients with preeclampsia, but not in normal pregnant women, the RBP4 concentrations had a significantly negative correlation with gestational age at blood collection (at the time of diagnosis of pre-eclampsia). Thus, the earlier the diagnosis, the higher was the maternal plasma RBP4 concentrations. This is pertinent since the timing of the diagnosis of preeclampsia is an important index of severity. The finding that preeclampsia is associated with higher circulating RBP4 concentrations is in agreement with a recent study by Atkinson et al. [4] in which a proteomic approach was used to identify novel biomarkers for preeclampsia. The authors found RBP4 to be differentially up-regulated (2.1-fold change) in the serum of patients with preeclampsia compared to matched healthy pregnant women [4].

Our results are in disagreement with the study reported by Stepan et al. [117] regarding RBP4 concentrations in maternal circulation. The authors found no significant differences in the mean maternal serum RBP4 concentration between patients with preeclampsia (n = 16) compared to normotensive controls (n = 20) admitted to the hospital for other obstetrical complications [117]. This apparent contradiction can be explained by differences in sample size, study population and inclusion criteria for the control group. In addition, the authors [117] did not differentiate between term and preterm preeclampsia. The relatively large sample size of our study allowed us to identify higher concentrations of circulating RBP4 in patients with early-onset preeclampsia.

Why is early-onset preeclampsia associated with elevated maternal RBP4 concentrations?

The cross-sectional nature of our study does not allow us to discern a cause-effect relationship between elevated maternal plasma RBP4 concentrations and preeclampsia; however, several suggestions for this finding can be raised:

1. An activation of the immune response has been implicated as a cause of endothelial cell dysfunction and preeclampsia [36, 97, 99]. Adhesion molecules play a central role in the adherence of leukocytes to endothelial cells and the subsequent migration of white blood cells into perivascular tissue and have been implicated in the pathophysiology of preeclampsia [16]. A recent study [90] in adults with newly diagnosed type 2 DM reported a positive correlation between RBP4 and soluble adhesion molecules such as sICAM-1 and sE-selectin. It was sug-

gested that RBP4 might be responsible for up-regulating endothelial adhesion molecules and the development of vascular complications in type 2 DM [8, 56]. Furthermore, RBP4 inhibits insulin action in endothelial cells, leading to impaired NO-dependent vasodilation [127]. Thus, the increased maternal plasma RBP4 concentration in patients with preeclampsia may be an additional marker of endothelial dysfunction [90].

2. Several hallmarks of the metabolic syndrome, which includes abdominal obesity, high level of triglycerides, low level of high-density lipoprotein, cholesterol, high blood pressure, and high fasting glucose are well established risk factors for preeclampsia [29, 34, 42, 48, 50, 52, 54, 110, 115, 131]. Similar to the metabolic syndrome, preeclampsia is emerging as a risk factor for cardiovascular complications later in life [9, 33, 44, 96, 109, 113, 114, 130]. Importantly, Bellamy et al. [9] reported in a recent meta-analysis that women who had preterm preeclampsia had the greatest risk of future cardiovascular disease, and this was higher than those who had severe preeclampsia, supporting the concept that timing of onset of preeclampsia more accurately reflects the severity of the maternal cardiovascular phenotype [9]. Elevated circulating RBP4 concentration has been linked to insulin resistance [21, 40, 132], a core component of the metabolic syndrome. Moreover, it has been associated with a subclinical cardiovascular disease in the elderly [47]. Thus, the elevated RBP4 concentration found in patients with early-onset preeclampsia may be a marker for a subclinical metabolic syndrome, which is reflected by the greater risk of cardiovascular complications in later life observed in these women compared to those with term preeclampsia [9].

3. Serum RBP4 concentration has been shown to be elevated in patients with impaired kidney function [94, 104]. In addition, it has been suggested that the increased RBP concentration observed in patients with type 2 DM may be due to impaired kidney function rather than the diabetic state itself [46, 67]. During normal pregnancy, the urinary excretion of RBP is greater than in the non-pregnant state, and increases from the first to the second and third trimester [7, 35]. It is possible that the impaired renal function that accompanies preeclampsia, especially in its more severe form, may lead to decreased glomerular filtration rate and decreased excretion of RBP4 in urine. In our study, a significantly higher proportion of patients with early-onset preeclampsia (<32 weeks) had a urine dipstick measurement ≥3+ protein compared to those diagnosed with preeclampsia later in pregnancy (86% [24/28] vs. 64% [49/76], P = 0.03).

4. The lack of correlation between circulating RBP4 concentrations and obesity-related parameters demonstrated in our study and those of others [117, 124], leads to the suggestion that the liver, rather than adipose tissue, may be involved in regulating the circulating RBP4 concentration [13]. It may be that the differences in the RBP4 concentration between normal pregnant women and those

with early-onset preeclampsia are related to liver dysfunction. Hepatic fat accumulation has been demonstrated to increase RBP4 [107, 116] and a positive association between alanine aminotransferase and RBP4 concentrations has been recently suggested [98]. In our study, there was a trend toward a higher rate of elevated liver function tests (aspartate aminotransferase >70 IU/L) in patients with early-onset preeclampsia than in those with preeclampsia later in pregnancy (23% [6/23] vs. 11% [8/73], respectively; $P=0.1$).

RBP4 concentrations in maternal blood are not associated with SGA or FD

Although preeclampsia, SGA and FD share several common mechanisms of disease, we did not find an association between circulating maternal RBP4 and pregnancies complicated by an SGA infant or an FD. These findings suggest that RBP4 does not play a role in the pathophysiology of these obstetrical syndromes among normotensive pregnant women. The elevated concentrations of RBP4 found only in patients with early-onset preeclampsia could be explained by different mechanisms of disease distinguishing this complication from SGA or FD. While the clinical manifestations of preeclampsia involve mainly the maternal compartment, SGA and FD are primarily a consequence of a fetal disease. Thus, the increased circulating RBP4 concentrations in preeclampsia may reflect an exaggerated maternal inflammatory response, a subclinical metabolic syndrome or other aspects of disease such as renal or liver dysfunction associated with preeclampsia.

In conclusion, we were able to demonstrate, for the first time, an association between higher maternal circulating RBP4 concentration and preeclampsia, specifically among patients with early-onset preeclampsia. Such an association was not evident among normotensive pregnant women with either an SGA neonate or an FD. Further studies are needed in order to elucidate the relationship between maternal circulating RBP4 concentration and preeclampsia.

Acknowledgements

References

[1] ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67.

[2] Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser. 2003;916:i–viii, 1–149, backcover.

[3] Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol. 1996;87:163–8.

[4] Atkinson KR, Blumenstein M, Black MA, Wu SH, Kasabov N, Taylor RS, et al. An altered pattern of circulating apolipoprotein E3 isoforms is implicated in preeclampsia. J Lipid Res. 2009;50:71–80.

[5] Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007;92:1971–4.

[6] Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 2003;27:987–91.

[7] Beetham R, Dawnay A, Menabawy M, Silver A. Urinary excretion of albumin and retinol-binding protein during normal pregnancy. J Clin Pathol. 1988;41:1089–92.

[8] Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol. 2002;90: 40L–8L.

[9] Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J. 2007;335:974–7.

[10] Bernotiene E, Palmer G, Talabot-Ayer D, Szalay-Quinodoz I, Aubert ML, Gabay C. Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice. Arthritis Res Ther. 2004;6:R256–63.

[11] Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789–95.

[12] Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol. 1993;100:989–94.

[13] Broch M, Auguet MT, Ramirez R, Olona M, Aguilar C, Megia A, et al. Parallel down-regulation of retinol binding protein-4 (RBP4) and adiponectin expression in subcutaneous adipose tissue of non-morbidly obese subjects. Eur J Endocrinol. 2009;16:87–94.

[14] Brosens IA. Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol. 1977;4:573–93.

[15] Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of pre-eclampsia. J Pathol. 1970;101:vi.

[16] Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med. 2002;12:19–27.

[17] Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award. Am J Obstet Gynecol. 2004;190:1541–7.

[18] Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17:3–18.

[19] Chan TF, Chen HS, Chen YC, Lee CH, Chou FH, Chen IJ, et al. Increased serum retinol-binding protein 4 concentrations in women with gestational diabetes mellitus. Reprod Sci. 2007;14:169–74.

[20] Chesley SC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol. 1976;124:446–59.

[21] Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29:2457–61.

[22] Clark BA, Halvorson L, Sachs B, Epstein FH. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol. 1992;166:962–8.

[23] Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med. 1998;338:147–52.

[24] Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf). 2007;66:447–53.

[25] D'Anna R, Baviera G, Corrado F, Giordano D, De VA, Nicocia G, et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. Br J Obstst Gynecol. 2006; 113:1264–9.

[26] De Wolf F, Brosens I, Renaer M. Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension. Br J Obstet Gynaecol. 1980;87:678–85.

[27] Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998; 179:1359–75.

[28] Demmer LA, Birkenmeier EH, Sweetser DA, Levin MS, Zollman S, Sparkes RS, et al. The cellular retinol binding protein II gene. Sequence analysis of the rat gene, chromosomal localization in mice and humans, and documentation of its close linkage to the cellular retinol binding protein gene. J Biol Chem. 1987;262:2458–67.

[29] Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. J Am Med Assoc. 1991;266: 237–41.

[30] Espinoza J, Nien JK, Kusanovic JP, Goncalves LF, Medina LH, Gomez R, et al. The combined use of uterine artery Doppler and maternal plasma placental growth factor concentrations identifies patients at risk for early onset and/or severe preeclampsia. Ultrasound Obstet Gynecol. 2006;28: 387–8.

[31] Espinoza J, Romero R, Nien JK, Kusanovic JP, Richani K, Gomez R, et al. A role of the anti-angiogenic factor s-VEGFR-1 in the ''mirror syndrome'' (Ballantyne's syndrome). J Matern Fetal Neonatal Med. 2006;19:607–13.

[32] Esposito K, Pontillo A, Di PC, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc. 2003;289:1799–804.

[33] Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, et al. Long-term mortality after preeclampsia. Epidemiology. 2005;16:206–15.

[34] Garner PR, D'Alton ME, Dudley DK, Huard P, Hardie M. Preeclampsia in diabetic pregnancies. Am J Obstet Gynecol. 1990;163:505–8.

[35] Gero G, Anthony F, Rowe DJ, Dennis KJ. Increased urinary excretion of retinol-binding protein during normal pregnancies. Clin Chem. 1986;32:916–7.

[36] Gervasi MT, Chaiworapongsa T, Pacora P, Naccasha N, Yoon BH, Maymon E, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol. 2001;185:792–7.

[37] Giacoia GP. Concentration of serum prealbumin and retinol-binding proteins during pregnancy. South Med J. 1984;77: 1261–3.

[38] Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203:2165–75.

[39] Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension. 2007; 49:1056–62.

[40] Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354:2552–63.

[41] Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9:147–60.

[42] Gratacos E, Casals E, Sanllehy C, Cararach V, Alonso PL, Fortuny A. Variation in lipid levels during pregnancy in women with different types of hypertension. Acta Obstet Gynecol Scand. 1996;75:896–901.

[43] Guler N, Kirerleri E, Ones U, Tamay Z, Salmayenli N, Darendeliler F. Leptin: does it have any role in childhood asthma? J Allergy Clin Immunol. 2004;114:254–9.

[44] Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart. 1997;77:154–8.

[45] Hendler I, Blackwell SC, Mehta SH, Whitty JE, Russell E, Sorokin Y, et al. The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. Am J Obstet Gynecol. 2005;193:979–83.

[46] Henze A, Frey SK, Raila J, Tepel M, Scholze A, Pfeiffer AF, et al. Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4 serum levels. Diabetes. 2008;57:3323–6.

[47] Ingelsson E, Lind L. Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care. 2009;32:733–5.

[48] Innes KE, Wimsatt JH, McDuffie R. Relative glucose tolerance and subsequent development of hypertension in pregnancy. Obstet Gynecol. 2001;97:905–10.

[49] Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long-term mortality of mothers and fathers after pre-eclampsia: population based cohort study. Br Med J. 2001;323:1213–7.

[50] Isezuo SA, Ekele BA. Comparison of metabolic syndrome variables among pregnant women with and without eclampsia. J Natl Med Assoc. 2008;100:1059–62.

[51] Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 2002;186:158–66.

[52] Joffe GM, Esterlitz JR, Levine RJ, Clemens JD, Ewell MG, Sibai BM, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1998; 179:1032–7.

[53] Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand. 1995;74:772–6.

[54] Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism. 1999;48:892–6.

[55] Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest. 1968;47:2025–44.

[56] Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676–81.

[57] Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol. 1997;38:302–6.

[58] Kusanovic JP, Romero R, Mazaki-Tovi S, Chaiworapongsa T, Mittal P, Gotsch F, et al. Resistin in amniotic fluid and its association with intra-amniotic infection and inflammation. J Matern Fetal Neonatal Med. 2008;21:902–16.

[59] Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.

[60] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.

[61] Lindheimer MD. Hypertension in pregnancy. Hypertension. 1993;22:127–37.

[62] Liou GI, Fong SL, Gosden J, van TP, Ledbetter DH, Christie S, et al. Human interstitial retinol-binding protein (IRBP): cloning, partial sequence, and chromosomal localization. Somat Cell Mol Genet. 1987;13:315–23.

[63] Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897–901.

[64] Lu D, Yang X, Wu Y, Wang H, Huang H, Dong M. Serum adiponectin, leptin and soluble leptin receptor in preeclampsia. Int J Gynaecol Obstet. 2006;95:121–6.

[65] Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol. 1997;104:223–8.

[66] Makover A, Soprano DR, Wyatt ML, Goodman DS. Localization of retinol-binding protein messenger RNA in the rat kidney and in perinephric fat tissue. J Lipid Res. 1989;30:171–80.

[67] Masaki T, Anan F, Tsubone T, Gotoh K, Chiba S, Katsuragi I, et al. Retinol binding protein 4 concentrations are influenced by renal function in patients with type 2 diabetes mellitus. Metabolism. 2008;57:1340–4.

[68] Mazaki-Tovi S, Kanety H, Sivan E. Adiponectin and human pregnancy. Curr Diab Rep. 2005;5:278–81.

[69] Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Schiff E, Sivan E. Cord blood adiponectin in large-for-gestational age newborns. Am J Obstet Gynecol. 2005;193:1238–42.

[70] Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, et al. Maternal serum adiponectin levels during human pregnancy. J Perinatol. 2007;27:77–81.

[71] Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Efraty Y, Schiff E, et al. Determining the source of fetal adiponectin. J Reprod Med. 2007;52:774–8.

[72] Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Yinon Y, Wiser A, et al. Adiponectin and leptin concentrations in dichorionic twins with discordant and concordant growth. J Clin Endocrinol Metab. 2009;94:892–8.

[73] Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Visfatin in human pregnancy: maternal gestational diabetes vis-a-vis neonatal birthweight. J Perinat Med. 2009;37:218–31.

[74] Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Gotsch F, et al. Adiponectin multimers in maternal plasma. J Matern Fetal Neonatal Med. 2008;21:796–815.

[75] Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Mittal P, et al. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition. J Perinat Med. 2008;36:485–96.

[76] Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Maternal visfatin concentration in normal pregnancy. J Perinat Med. 2009;37:206–17.

[77] Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Chaiwaropongsa T, Mittal P, et al. Maternal plasma visfatin in preterm labor. J Matern Fetal Neonatal Med. 2009; DOI: 10.1080/14767050902994788.

[78] Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Dysregulation of maternal serum adiponectin in preterm labor. J Matern Fetal Neonatal Med. 2009; DOI: 10.1080/14767050902994655.

[79] Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Gotsch F, et al. Maternal serum adiponectin multimers in preeclampsia. J Perinat Med. 2009;37:349–63.

[80] Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Maternal serum adiponectin multimers in gestational diabetes. J Perinat Med. 2009; DOI: 10.1515/JPM.2009.101.

[81] Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Maternal serum adiponectin multimers in patients with a small-for-gestational-age newborn. J Perinat Med. 2009; DOI: 10.1515/JPM.2009.128.

[82] Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Mittal P, et al. Adiponectin in amniotic fluid in normal pregnancy, spontaneous labor at term, and preterm labor: a novel association with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2009; DOI: 10.1080/14767050903026481.

[83] Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101:669–74.

[84] Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes. 1998;47:1384–91.

[85] Myatt L. Role of placenta in preeclampsia. Endocrine. 2002;19:103–111.

[86] Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Adiponectin in severe preeclampsia. J Perinat Med. 2007;35:503–12.

[87] Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, et al. Resistin: a hormone which induces insulin

resistance is increased in normal pregnancy. J Perinat Med. 2007;35:513–21.

[88] Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. J Perinat Med. 2007;35:522–31.

[89] Pacora P, Romero R, Mazaki-Tovi S, Kusanovic JP, Mittal P, Than NG, et al. Adiponectin: A missing link between FD and altered metabolic inflammatory and anti-angiogenic states? Reprod Sci. 2009;16:247A.

[90] Park SE, Kim DH, Lee JH, Park JS, Kang ES, Ahn CW, et al. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis. 2008;204:23–5.

[91] Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 1991;98:648–55.

[92] Poston L, Chappell LC. Is oxidative stress involved in the aetiology of pre-eclampsia? Acta Paediatr Suppl. 2001;90: 3–5.

[93] Quadro L, Hamberger L, Colantuoni V, Gottesman ME, Blaner WS. Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models. Mol Aspects Med. 2003;24: 421–30.

[94] Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AF, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int. 2007;72:505–11.

[95] Ramsay JE, Jamieson N, Greer IA, Sattar N. Paradoxical elevation in adiponectin concentrations in women with pre-eclampsia. Hypertension. 2003;42:891–4.

[96] Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797–803.

[97] Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499–506.

[98] Ribel-Madsen R, Friedrichsen M, Vaag A, Poulsen P. Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes. 2009;58:54–60.

[99] Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200–4.

[100] Robertson WB, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. Perspect Nephrol Hypertens. 1976;5:115–27.

[101] Rocchi M, Covone A, Romeo G, Faraonio R, Colantuoni V. Regional mapping of RBP4 to 10q23----q24 and RBP1 to 3q21----q22 in man. Somat Cell Mol Genet. 1989;15: 185–90.

[102] Romero R. Prenatal medicine: the child is the father of the man. Prenat Neonat Med. 1996;1:8–11.

[103] Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9–23.

[104] Scarpioni L, Dall'aglio PP, Poisetti PG, Buzio C. Retinol binding protein in serum and in urine of glomerular and tubular nephropathies. Clin Chim Acta. 1976;68:107–13.

[105] Schaffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Scholmerich J, et al. Adipocytokines in synovial fluid. J Am Med Assoc. 2003;290:1709–10.

[106] Seely EW. Hypertension in pregnancy: a potential window into long-term cardiovascular risk in women. J Clin Endocrinol Metab. 1999;84:1858–61.

[107] Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol. (Oxf). 2008;68:555–60.

[108] Sheppard BL, Bonnar J. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol. 1981;88:695–705.

[109] Sibai BM, Sarinoglu C, Mercer BM. Eclampsia VII. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol. 1992;166:1757–61.

[110] Sibai BM, Gordon T, Thom E, Caritis SN, Klebanoff M, McNellis D, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 1995;172:642–8.

[111] Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1997;177:1003–10.

[112] Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–101.

[113] Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001;357:2002–6.

[114] Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, et al. A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009;200:58 e1–8.

[115] Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension. 2001;37:232–9.

[116] Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007;30:1173–8.

[117] Stepan H, Ebert T, Schrey S, Reisenbuchler C, Bluher M, Stumvoll M, et al. Preliminary report: Serum levels of retinol-binding protein 4 in preeclampsia. Metabolism. 2009; 58:275–7.

[118] Tamori Y, Sakaue H, Kasuga M. RBP4, an unexpected adipokine. Nat Med. 2006;12:30–1.

[119] Taylor RN, de Groot CJ, Cho YK, Lim KH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998; 16:17–31.

[120] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–83.

[121] Tilg H, Moschen AR. Role of adiponectin and PBEF/vis-fatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond). 2008;114:275–88.

[122] Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol. 1998;179: 1539–44.

[123] Tuzun A, Uygun A, Yesilova Z, Ozel AM, Erdil A, Yaman H, et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 2004;19:429–32.

[124] Ueland T, Dalsoren T, Voldner N, Godang K, Henriksen T, Bollerslev J. Retinol-binding protein-4 is not strongly associated with insulin sensitivity in normal pregnancies. Eur J Endocrinol. 2008;159:49–54.

[125] Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, Erez O, Than NG, Kim SK, et al. Retinol binding protein 4: an adipokine associated with intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2009. (in press).

[126] Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.

[127] Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003;285:E123–9.

[128] Wakatsuki A, Ikenoue N, Okatani Y, Shinohara K, Fukaya T. Lipoprotein particles in preeclampsia: susceptibility to oxidative modification. Obstet Gynecol. 2000;96:55–9.

[129] Weiss JL, Malone FD, Emig D, Ball RH, Nyberg DA, Comstock CH, et al. Obesity, obstetric complications and cesa-rean delivery rate – a population-based screening study. Am J Obstet Gynecol. 2004;190:1091–7.

[130] Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br Med J. 2003;326:845.

[131] Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent pre-eclampsia: a prospective study. J Clin Endocrinol Metab. 2002;87:1563–8.

[132] Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–62.

[133] Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86:3815–9.

[134] Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab. 2007;92:2590–7.